InvestSMART

Pro Medicus Limited (ASX:PME)

ALERT: Price-sensitive ASX Announcement for PME
Current share price for PME : $193.350 23.88 (14.09%)+
Announcement
Release
12 Feb 2026 9:49AM
Price at Release
$169.470
Full Release
download
Summary
Pro Medicus Limited (PME) reported a robust HY26 financial performance, with a 28.4% increase in revenue and a 230.9% rise in profit after tax. This period marked the most successful half in the company's history, driven by securing seven new contracts valued over A$280 million and significant progress in cloud-based implementations. The company remains debt-free and continues to expand its market presence, particularly in North America. Their operational model focuses on SaaS delivery, aiming for a substantial forward revenue stream. AI and technology integration remain crucial to their growth strategy, with Visage 7 enhancing radiologist efficiency and clinical accuracy. Pro Medicus is well-positioned to leverage AI advancements and maintain its market leadership.
Key Points
  • Pro Medicus Limited (PME) reported a record half year with substantial revenue and profit growth.
  • HY26 revenue increased by 28.4% to $124.8 million and profit after tax surged by 230.9% to $171.2 million.
  • The company secured seven new contracts worth over A$280 million and completed multiple cloud-based implementations.
  • Pro Medicus maintains a strong financial position, being debt-free with increased cash and investments.
  • The operational model focuses on SaaS delivery and transaction-based revenue, with a forward revenue of over A$1,080 million for five years.
  • Strategic focus includes expanding the North American market and leveraging AI technologies.
  • Visage 7 platform demonstrated scalability and efficiency, offering solutions like 'full stack' and cloud-based services.
  • Investments in AI, including partnerships with leading institutions, are part of their growth strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.